ASLAN Pharmaceuticals Completes Enrolment in Second Cohort and Opens New Sites in US and Australia in ASLAN004 Atopic Dermatitis Study
September 21, 2020 06:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Sept. 21, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to...
ASLAN Pharmaceuticals Resumes Recruitment of New Patients Into ASLAN004 Study
August 24, 2020 03:27 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Aug. 24, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative...
Kymab Announces Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic Dermatitis
August 11, 2020 04:06 ET
|
Kymab Group Ltd
Kymab Announces Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic Dermatitis KY1005 met both primary end points demonstrating: A clinically meaningful improvement in disease activity...
Derm-Biome Pharmaceuticals, Inc raises pre-seed funding, spins out new company focused on chronic inflammatory diseases
July 02, 2020 11:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, July 02, 2020 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on skin diseases and healthy ageing,...
MatriSys Bioscience Inc. is pleased to announce that we have been selected as a CONNECT 2020 Cool Company
May 28, 2020 14:11 ET
|
MatriSys Bioscience
SAN DIEGO, May 28, 2020 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics is pleased to announce that it was named a 2020 “Cool Company” by...
MatriSys Bioscience Inc. is pleased to announce that Magda Marquet PhD has been appointed Chairwoman of MatriSys’ Board of Directors
May 26, 2020 12:25 ET
|
MatriSys Bioscience
SAN DIEGO, May 26, 2020 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics, is pleased to announce that Magda Marquet PhD has been appointed...
Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Atopic Dermatitis
March 24, 2020 08:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, March 24, 2020 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a private Vancouver based start-up biopharmaceutical company focused on skin health and healthy...
New Eczema Report Depicts Enormous Burdens and Huge Unmet Medical Needs
March 18, 2020 11:00 ET
|
Asthma and Allergy Foundation of America
Washington, D.C., March 18, 2020 (GLOBE NEWSWIRE) -- Today, five organizations jointly release the “More Than Skin Deep” Voice of the Patient report summarizing outcomes from a September 2019...
ASLAN Pharmaceuticals Reports Positive Preliminary Data From Proof-of-Concept Study for ASLAN004 Targeting Atopic Dermatitis
December 02, 2019 02:07 ET
|
ASLAN PHARMACEUTICALS LIMITED
- ASLAN004 demonstrates early signs of efficacy in the low dose cohort of multiple ascending dose study - 3 patients completed 1 month of dosing and achieved average reduction in EASI score of 71%....
ASLAN Pharmaceuticals Enrolls First Patient in Proof-of-Concept Study for ASLAN004 Targeting Atopic Dermatitis
October 22, 2019 02:45 ET
|
ASLAN PHARMACEUTICALS LIMITED
- Multiple ascending dose study will assess the safety and efficacy of ASLAN004 in patients with moderate to severe atopic dermatitis - ASLAN004 has previously demonstrated a favourable tolerability...